Trial Profile
A Study to Evaluate the Effect of Sunitinib on Tumour Infiltration of CD8 T Cells and Modulation Of Their Function by Altering VEGF-Induced Upregulation of PD1 Expression in Patients With Renal Cell Carcinoma (RCC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2016
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Pharmacodynamics
- 05 Apr 2016 New trial record